Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

S. Z. Usmani, R. Sexton, S. Ailawadhi, J. J. Shah, J. Valent, M. Rosenzweig, B. Lipe, J. A. Zonder, S. Fredette, B. Durie, A. Hoering, B. Bartlett, R. Z. Orlowski

Research output: Contribution to journalLetterpeer-review

2 Scopus citations

Fingerprint Dive into the research topics of 'Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211'. Together they form a unique fingerprint.